MOYES JAY M sold $159K of PBYI
MOYES JAY M sold 22,000 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $7.22 ($0.16M total) on 2026-06-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the director’s open-market sale of 22,000 shares at $7.2180 on 2026-06-12, with holdings after the trade of 58,322 shares.
Market read
This is a routine insider sale disclosure; it may cause brief sentiment noise but does not provide new operational or financial information.
What to watch
Because the sale is under a 10b5-1 plan, the disclosure may not reflect new negative expectations; position size and broader insider activity would matter more than this single print.
Background
The article is an SEC Form 4 insider transaction report for PUMA BIOTECHNOLOGY, INC. (PBYI).
Ticker impact
Puma Biotechnology director Moyes Jay M sold 22,000 shares in an open-market transaction for about $158,796 under a 10b5-1 plan.
Likely minimal price impact; any reaction should fade unless accompanied by other company-specific news.
The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through from a single director 10b5-1 sale.
None indicated.
None indicated.
Counterpoint
Traders may treat the sale as a non-informational liquidity event and ignore it, focusing instead on fundamentals and upcoming catalysts.
Key entities
- issuerPBYI
Puma Biotechnology, Inc., the company whose director transaction is disclosed.
- insiderMOYES JAY M
Director who executed the open-market sale under a Rule 10b5-1 plan.
